Clearside Biomedical announces plan to explore options

Clearside Biomedical announces plan to explore options

Clearside Biomedical, Inc. (Nasdaq: CLSD) has announced plans to explore various strategic alternatives to advance its proprietary suprachoroidal space (SCS) delivery platform and promising ophthalmology pipeline. The company has retained Piper Sandler, a leading investment bank, to support this strategic evaluation process. Potential alternatives include the sale, license, monetization, or divestiture of assets, collaboration, partnership, merger, acquisition, or joint ventures [1].

The decision to explore these options comes amidst an unpredictable economic environment and challenging fundraising conditions in the biopharmaceutical industry. Clearside's SCS Microinjector enables a proven in-office, repeatable, non-surgical procedure for the targeted delivery of a wide variety of therapies to the macula, retina, or choroid. The company's first commercial product, XIPERE® (triamcinolone acetonide injectable suspension), is approved in the U.S., Singapore, and Australia, and is under regulatory review in China and Canada [1].

Clearside's lead program, CLS-AX (axitinib injectable suspension), is in development for the treatment of wet AMD. The company has successfully completed Phase 2b clinical trials and aligned with the FDA on a Phase 3 development plan. The SCS Microinjector has demonstrated meaningful potential in various ophthalmic disorders, including geographic atrophy (GA) and diabetic macula edema (DME) [1].

To facilitate the strategic review process and conserve cash, Clearside has transitioned all employees, including executive officers, into consulting roles and paused internal research and development programs. The company has not set a timetable for the strategic review process and intends to provide updates only when the Board approves a specific action or determines that disclosure is appropriate [1].

Clearside Biomedical is a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space. The company's SCS injection platform has been used in commercial ophthalmic products and clinical development programs by various partners, including Aura Biosciences, Bausch + Lomb, BioCryst Pharmaceuticals, REGENXBIO, Arctic Vision, and Santen [1].

References:
[1] https://www.globenewswire.com/news-release/2025/07/17/3117105/0/en/Clearside-Biomedical-Announces-Plan-to-Explore-Strategic-Alternatives-to-Advance-its-Proprietary-Suprachoroidal-SCS-Delivery-Platform-and-Promising-Ophthalmology-Pipeline.html